Article

The development of a new fusion inhibitor for the treatment of HIV

2017-01-01

Abstract excerpt

Since the introduction of combination antiretroviral therapy (ART), there has been a dramatic improvement in the prognosis of people living with HIV. Indeed, data from numerous cohorts now show that for people commenced on ART at high CD4 counts and who are retained in care, life expectancy is similar to matched HIV-negative people. Consequently, the number of years an individual diagnosed with HIV can expect to b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7c407a4d-a1f6-5b2b-9f68-558e5336c328
DOI: 10.25560/50677

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The development of a new fusion inhibitor for the treatment of HIVDOI 10.25560/50677Read

Enfuvirtide: the first HIV fusion inhibitorSemantic proximity Read

Resistance to enfuvirtide, the first HIV fusion inhibitor.Semantic proximity Read

New nucleoside reverse transcriptase inhibitors for the treatment of HIV infectionsSemantic proximity Read

Novel Therapies Based on Mechanisms of HIV-1 Cell EntrySemantic proximity Read

HIV fusion and its inhibition in antiretroviral therapySemantic proximity Read

HIV-1 Entry and Membrane Fusion InhibitorsSemantic proximity Read

Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 – 2014)Semantic proximity Read

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Semantic proximity Read

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV InfectionSemantic proximity Read

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.Semantic proximity Read

Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency VirusSemantic proximity Read